Key facts
- It has raised $3.3M; the latest was Seed Round ($2.8M) in Nov 2025.
- Notable investors include Y Combinator, Soma Capital, Frontline Ventures, Pace Ventures, Saras Capital (England) — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Cellbyte
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellbyte are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellbyte
Developer of a platform designed to automate repetitive workflows and support a robust data foundation for faster drug launches. The company offers automated workflow capabilities and an integrated data backbone, enabling pharmaceutical teams to accelerate therapeutic development and deliver treatments to patients more quickly.
- Sector
- Healthcare
- HQ
- Munich, Germany
- Employees
- 10
- Website
- cellbyte.com/
- Ownership
- Privately Held (backing)
Cellbyte doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellbyte shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellbyte in its N-PORT filings yet. We sweep new filings monthly.